Lineage Cell Therapeutics Agrees to Acquire NeuroAirmid for $2.4 Million
The biotechnology company agreed to acquire NeuroAirmid Therapeutics for $2.4 million. NeuroAirmid also entered a license agreement with the University of California Regents related to a neural cell therapy program.
By Katherine HamiltonLineage Cell Therapeutics agreed to acquire the biotechnology company NeuroAirmid Therapeutics for $2.4 million.In connection with the deal, NeuroAirmid entered a license agreement with The Regents of the University of California related to a neural cell therapy program called…